Deucravacitinib - CAS 1609392-27-9

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.

Interleukin, JAK, Tyrosine Kinases, IFNAR

Chromatin/Epigenetic, Immunology/Inflammation, Angiogenesis, Stem Cells, Tyrosine Kinase/Adaptors, JAK/STAT signaling

1609356

>99.99%

C20H19D3N8O3

425.46

[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC

-20°C

Ice Packs

Isotope products